Model-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types
Zhao, X., Shen, J., Gopalakrishnan, M., Feng, Y., Schmidt, B.J., Statkevich, P., Kelleher, T., Rashford, M., Ivaturi, V., Gobburu, J.V.S., Agrawal, S., Bello, A., Roy, A.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article